ETEST Gepotidacin (GEP) (0.016-256 µg/mL)
bioMérieux SA · Decision date Apr 21, 2026
What did the FDA decide?
FDA records K260447 as a 510(k) premarket notification, with a decision dated Apr 21, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Apr 21, 2026
Regulatory record facts
- Identifier
- K260447
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- bioMérieux SA
- Product code
- JWY
- Decision code
- SESE
- Decision date
- Apr 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Manual Antimicrobial Susceptibility Test Systems.
- Applicant
- bioMérieux SA
- Product code
- JWY
- FDA device class
- 2
FDA decision timeline
K260447 received
Application receipt date recorded by FDA.
K260447 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code JWY
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Liofilchem s.r.l. | 510(k) clearance | Apr 17, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
bioMérieux SA
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Marcy-L'Etoile
Sources and methodology
- Original FDA record: K260447
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records